Minerva Neurosciences | NERV - Cost Of Sales

Stock Price
6.27
Daily Change
-0.04 -0.63%
Monthly
45.14%
Yearly
219.90%
Q1 Forecast
2.46

Minerva Neurosciences reported 386K in Cost of Sales for its fiscal quarter ending in June of 2024.





Cost Of Sales Change Date
Acadia Pharmaceuticals USD 21.65M 913K Sep/2025
Adma Biologics USD 58.64M 3.88M Sep/2025
ALKERMES USD 51.59M 2.13M Sep/2025
AstraZeneca USD 3.27B 471M Dec/2025
BioCryst Pharmaceuticals USD 12.27M 9.04M Dec/2024
Bristol-Myers Squibb USD 4.92B 657M Dec/2025
Cipla INR 29.1B 1.16B Dec/2025
Clal Biotechnology ILS 16.49M 2.64M Jun/2022
Compugen USD 1.65M 10K Sep/2025
CSL USD 1.79B 2.15B Jun/2025
Dynavax Technologies USD 14.4M 368K Sep/2025
Eli Lilly USD 3.37B 363.7M Dec/2025
Esperion Therapeutics USD 51.63M 22.2M Sep/2024
GlaxoSmithKline GBP 2.61B 377M Dec/2025
Grifols EUR 1.32B 22.75M Sep/2025
Halozyme Therapeutics USD 73M 8.88M Sep/2025
Ionis Pharmaceuticals USD 2.34M 1.81M Sep/2025
J&J USD 7.97B 689M Dec/2025
Merck USD 3.32B 531M Dec/2025
Minerva Neurosciences 386K 31K Jun/2024
Neurocrine Biosciences USD 264M 252.7M Sep/2025
Novartis USD 3.54B 217M Sep/2025
Novavax USD 60.62M 91.77M Sep/2024
Pfizer USD 6.29B 2.12B Dec/2025
Roche Holding CHF 8.48B 4.61B Dec/2025
Sanofi EUR 4.29B 421M Dec/2025
Takeda JPY 401.15B 184.07B Dec/2025
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024